Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246914 | 1.00 | CES1 (0.47) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| SCHEMBL236357 | 1.00 | CES1 (0.47) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| Hydrochloric Acid SCHEMBL8829227 | 0.98 | CES1 (0.46) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| Hydrochloric Acid SCHEMBL5595770 | 0.98 | CES1 (0.46) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| Hydrochloric Acid SCHEMBL4926039 | 0.98 | CES1 (0.46) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| SCHEMBL12341938 | 0.89 | CES1 (0.44) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| SCHEMBL464445 | 0.89 | CES1 (0.44) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| SCHEMBL686435 | 0.89 | CES1 (0.44) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| SCHEMBL7436744 | 0.89 | CES1 (0.44) | CES1KCNN4CYP1A2PTPN1ENPP2 | |
| SCHEMBL8887284 | 0.87 | MAPT (0.48) | CES1KCNN4CYP1A2PTPN1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688761-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Tonix Pharma Limited (IE) | 2026-02-11 | — | — | EP | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2025036442-A1 | METHOD FOR PREPARING PYRAZINONAPHTHYRIDINE DIONE COMPOUND, AND INTERMEDIATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-02-20 | — | — | WO | claimed |
| WO-2024206520-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| CN-117105931-A | Method for preparing pyridopyrimidine compounds and intermediate thereof | 上海翰森生物医药科技有限公司 | 2023-11-24 | — | — | CN | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| CN-112739686-A | Novel process for the preparation of (-) -xylometazoline succinate | 赛特瑞恩股份有限公司 | 2021-04-30 | — | — | CN | claimed |
| WO-2020067684-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | (주)셀트리온 | 2020-04-02 | — | — | WO | claimed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | CES1 3892/4885KCNN4 4275/4885CYP1A2 908/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | CES1 558/4885KCNN4 3027/4885CYP1A2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.